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Abstract In this paper we present a mathematical anal-
ysis of the basic model for target mediated drug disposition
(TMDD). Assuming high afﬁnity of ligand to target, we
give a qualitative characterisation of ligand versus time
graphs for different dosing regimes and derive accurate
analytic approximations of different phases in the temporal
behaviour of the system. These approximations are used to
estimate model parameters, give analytical approximations
of such quantities as area under the ligand curve and
clearance. We formulate conditions under which a suitably
chosen Michaelis–Menten model provides a good approx-
imation of the full TMDD-model over a speciﬁed time
interval.
Keywords Target   Receptor   Antibodies   Drug-
disposition   Michaelis–Menten   Quasi-steady-state  
Quasi-equilibrium   Singular perturbation
Introduction
The interaction of ligand and target in the process of
drug-disposition offers interesting examples of complex
dynamics when target is synthesised and degrades and
when both ligand and ligand–target complex are elimi-
nated. In recent years such dynamics has received con-
siderable attention because it is important in the context of
data analysis, but also, more generally, in the context of
system biology because this model serves as a module in
more complex systems [1].
Based on conceptual ideas developed by Levy [2], the
basic model for target mediated drug disposition (TMDD)
was formulated by Mager and Jusko [3]. Earlier studies of
ligand–target interactions go back to Michaelis and Menten
[4]. We also mention ideas about receptor turnover
developed by Sugiyama and Hanano [5]. Mager and
Krzyzanski [6] showed how rapid binding of ligand to
target leads to a simpler model, Gibiansky et al. [7] studied
the related quasi-steady-state approximation to the model
and Marathe et al. [8] conducted a numerical validation of
the rapid binding approximation. Gibiansky et al. [9] also
pointed out a relation with the classical indirect response
model. For further background we refer to the books by
Meibohm [10] and Crommelin et al. [11], and to the
reviews by Lobo et al. [12] and Mager [13].
In practice, the Michaelis–Menten model is often used
when ligand curves exhibit TMDD characteristics (see e.g.
Bauer et al. [14]). Recently, Yan et al. [15] analysed the
relationship between TMDD- and Michaelis–Menten type
dynamics. We also mention the work by Krippendorff
et al. [16] which studies an extended TMDD system which
includes receptor trafﬁcking in the cell.
The characteristic features of TMDD dynamics were
ﬁrst studied in [3] under the condition of a constant target
pool, i.e., the total amount of target: free and bound, was
assumed to be constant in time. Under the same assump-
tion, a mathematical analysis of this model was offered by
Peletier and Gabrielsson [17]. This assumption was made,
in part for educational reasons, because it makes a
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itative and quantitative properties of the dynamics can be
identiﬁed and illustrated. In a recent paper Ma [18] com-
pared different approximate models under the same
assumption of a constant target pool.
In the present paper we extend this analysis to the full
TMDD model and do not make the assumption that the
target pool is constant. This means, in particular, that we
shall now also be enquiring as to how the target pool
changes over time and how it is affected by the dynamics
of its zeroth order synthesis and ﬁrst order degeneration.
The analysis in this paper consists of a combination of
numerical simulations based on a speciﬁc case study, and a
detailed mathematical analysis of the set of three differ-
ential equations that constitute the full TMDD model. Our
main objective will be to gain insight in such issues as:
1. Properties of concentration proﬁles When the initial
ligandconcentrationislargerthantheendogenousreceptor
concentration, the dynamics of target-mediated drug
disposition results in a characteristic ligand versus time
proﬁle. In Fig. 1 we show such a proﬁle schematically.
One can distinguish four different phases in the dynamics
of the system in which different processes are dominant:
(A)abriefinitialphase,(B)anapparentlinearphase,(C)a
transitionphaseand(D)alinearterminalphase.Weobtain
precise estimates for the duration of each of these phases
and for each of them we obtain accurate analytical
estimates for the concentration versus time graphs of the
ligand, the receptor and the ligand–receptor complex.
Onthebasisofligandconcentrationversustimecurveswe
will develop instruments for extracting information about
the target and the ligand–target complex versus time
curves.
2. Parameter identiﬁability We shed light on what we can
predict when we have only measured (a) the ligand,
(b) ligand and target, (c) ligand and complex, and
(d) all of the above.
3. Systems analysis Whilst focussing on concentration
versus time curves we gain considerable qualitative
understanding and quantitative estimates about the
impact of the different parameters in the model and on
quantities such as the area under the curve and time to
steady state of the different compounds.
4. Model comparison An important issue is the question
as to how the full TMDD model compares with the
simpler Michaelis–Menten model [7, 8, 15]. In this
paper we point out how the full model and the reduced
Michaelis–Menten model differ signiﬁcantly in the
initial second order phase and in the linear terminal
phase, in that the terminal rate (kz) of ligand in the full
model is much smaller than that in the Michaelis–
Menten model.
In this paper we focus on the classical TMDD model, as
presented in for instance [3] and shown schematically in
Fig. 2.However,sincewewillfocusonthetypicalfeaturesof
the interaction between the ligand L, the receptor R and their
complexRL, wedroptheperipheralcompartment(Vt, Cld)of
theligand.Inmathematicalterms,themodelthenresultsinthe
following system of ordinary differential equations:
dL
dt
¼ kf   konL   R þ koffRL   keðLÞL
dR
dt ¼ kin   koutR   konL   R þ koffRL
dRL
dt
¼ konL   R  ð koff þ keðRLÞÞRL
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Fig. 1 Characteristic ligand versus time graph in target-mediated
drug disposition. The concentration of the ligand is measured on a
logarithmic scale. In the ﬁrst phase (A) drug and target rapidly
equilibrate, in the second phase (B) the target is saturated and drug is
mainly eliminated directly by a ﬁrst order process, in the third phase
(C) the target is no longer saturated and drug is eliminated directly, as
well as in the form of a drug–target complex, and in the ﬁnal, fourth
phase (D) the drug concentration is so low that elimination is a linear
ﬁrst order process with direct as well as indirect elimination (as a
drug–target complex)
L  = Ligand
R = receptor 
RL = Receptor-Ligand 
complex 
R Vc, L  + RL
kin
kout
kon
koff
ke(RL)
InL 
Cl(L) 
Cld 
Vt
Fig. 2 Schematic description of target-mediated drug (or ligand)
disposition. The ligand L binds reversibly (kon/koff) to the target R to
form the ligand–target complex RL, which is irreversibly removed via
a ﬁrst order rate process (ke(RL)), and in addition is eliminated via a
ﬁrst order process (ke(L) = Cl(L)/Vc)
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tions, kf = InL/Vc denotes the infusion rate of the ligand
(here InL denotes the infusion of ligand and Vc the volume
of the central compartment), and kon and koff denote the
second-order on- and ﬁrst-order off rate of the ligand.
Ligand is eliminated according to a ﬁrst order process
involving the rate constant ke(L) = Cl(L)/Vc, where Cl(L)
denotes the clearance of ligand from the central compart-
ment. Ligand–target complex leaves the system according
to a ﬁrst order process with a rate constant ke(RL). Finally,
receptor synthesis and degeneration are, respectively, a
zeroth order (kin) process and a ﬁrst order (kout) process.
In the absence of a zeroth-order infusion of ligand, i.e.,
when kf = 0, the steady state of the system (1) is given by
L ¼ 0; R ¼ R0 ¼
def kin
kout
; RL ¼ 0 ð2Þ
Thus, this is the situation when there is no free or bound
ligand. The receptor concentration then satisﬁes a simple
turnover equation involving zeroth order synthesis and ﬁrst
order degeneration:
dR
dt
¼ kin   kout   R
with steady state R0 = kin/kout.
The TMDD system can be viewed as one in which two
constituents, the ligand and the target, or receptor, are inter-
acting with one another whilst each of them is supplied and
removed, either in their free form, or in combination in the
form of a complex. We shall ﬁnd that the total quantities of
ligand and receptor will play a central role. Therefore, we put
Ltot ¼ L þ RL and Rtot ¼ R þ RL ð3Þ
We deduce from the system (1) that their behaviour with
time is given by the following pair of conservation laws:
dLtot
dt
¼ kf   keðLÞL   keðRLÞRL fortheligandL
dRtot
dt ¼ kin   koutR   keðRLÞRL forthereceptorR
8
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ð4Þ
Note that in this system the on- and off rates of ligand to
receptor no longer appear.
We investigate the dynamics of the system (1) that is
generated by two types of administration of the ligand:
(i) Through a bolus dose. Then kf = 0. We denote the
initial ligand concentration by L(0) = L0 = D/Vc, where
D is the dose and Vc the volume of the central
compartment.
(ii) Through a constant rate infusion InL.T h e nkf = InL/
Vc[0 and L(0) = 0.
When we assume that prior to administration the system is
at baseline, the initial values of ligand, receptor and
ligand–receptor complex will be
Lð0Þ¼L0(bolus) orLð0Þ¼0(infusion);
Rð0Þ¼R0; RLð0Þ¼0 ð5Þ
In this paper we focus on the situation when ke(RL), koff and
ke(RL) are small compared to konR0.
Whereas in our earlier investigation [17], the total
amount of receptor was constant, because it was assumed
that ke(RL) = kout, here this assumption is no longer made
and, generally, Rtot will vary with time. However, we show
that there exists an upper bound for the total amount of
receptor in the system, free and bound, which is indepen-
dent of the amount of ligand supplied and holds for both
types of administration. Speciﬁcally, we prove that, starting
from baseline,
RtotðtÞ maxfR0;R g for allt 0 whereR  ¼
kin
keðRLÞ
ð6Þ
For the proof of this bound we refer to Appendix 3.
Anchoring our investigation in a case study in which
ligand is administered through a series of bolus doses, we
dissect the resulting time courses of the three compounds,
L, R and RL and identify characteristic phases, Phases A–D
shown in Fig. 1. We associate these phases with speciﬁc
processes and show, using singular perturbation theory
[19, 20, 21], that individual phases may be analysed
through appropriately chosen simpliﬁed models, yielding
accurate closed-form approximations. They offer tools
which may be used to compute critical quantities such as
residence time, and to verify whether different approxi-
mations to the full TMDD model, such as the rapid binding
approximation [6] and the quasi-steady-state approxima-
tion [7, 18] are valid in the different phases. These issues
are discussed at the conclusion of this paper.
Much of the mathematical analysis underpinning the
results presented throughout the text is presented in a series
of Appendices at the end of the paper.
Case study
The ligand, target and complex concentration–time courses
used throughout this analysis, were simulated to mimic real
experimental observations obtained on a monoclonal anti-
body dosed to marmoset monkeys. Simulated data were
generated with a constant coefﬁcient of variation (2 %) of
the error added to the data. Synthetic data were used for
pedagogic and proprietary reasons in order to answer the
question: ’’To what extent is the parameter precision
affected by including/not including target (R) and complex
(RL) data. The model used for generating the data is shown
in Fig. 2 and the actual parameters are stored in Table 1.
WinNonlin 5.2, with a Runge–Kutta–Fehlberg differential
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123equation solver, was used for both simulating and
regressing data. A constant CV (proportional error) model
was used as weighting function. All dose levels (Concen-
tration–time courses) were simultaneously regressed for the
ligand (L), ligand and target (L, R) and ligand, target and
complex (L, R and RL) data analyses, respectively. Kinetic
data of high quality—as regards spacing in time and con-
centration and very low error level—were used intention-
ally to demonstrate (a) improved precision when using two
or more sources of chemical entities; (b) as a check that
one gets back approximately the same parameter estimates
as used for generating the original dataset(s).
Data analysis
The case study is based on three sets of simulated con-
centration versus time data (I, II and III), each set of data
obtained after following four rapid intravenous injections
of the ligand or antibody (L). These datasets are shown in
Figs. 3 and 4. They are increasing in richness: the ﬁrst set
(I) contains ligand proﬁles only, the second set (II) contains
ligand as well as target or receptor proﬁles and the third set
(III) contains proﬁles of all three compounds: the ligand,
the receptor and the ligand–receptor complex.
The purpose of this study is to demonstrate the possi-
bility of ﬁtting the eight-parameter model shown in Fig. 2,
to three different sets of high quality data with increasing
richness, and show how precision of the estimates of the
model parameters increases when successively information
about target (II) and target and complex (III) is added. We
use this data set for two purposes: (i) for data analysis and
(ii) for highlighting critical features of the temporal
behaviour of the three compounds.
Simulated data from three sources (ligand, target and
complex) were intentionally used. We have experienced
that data of less quality gave biased and imprecise esti-
mates as well as biased and imprecise predictions of ligand,
target and complex.
The central volume Vc was assumed to be equal to 0.05
L/kg and ﬁxed. The other parameters are then re-estimated
Table 1 Pre-selected parameter values
Symbol Unit Value
Vt L/kg 0.1
Cld (L/kg)/h 0.003
Cl(L) (L/kg)/h 0.001
kon (mg/L)
-1/h 0.091
koff 1/h 0.001
kin (mg/L)/h 0.11
kout 1/h 0.0089
ke(RL) 1/h 0.003
R0 mg/L 12
0.001
0.01
0.1
1
10
100
1000
0 100 200 300 400 500 600
Time (h)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
m
g
/
L
)
Fig. 3 Semi-logarithmic graphs of the ligand plasma concentration
versus time after the administration of four rapid intravenous
injections D of 1.5, 5, 15 and 45 mg/kg, respectively (Data set (I)).
The volume of the central compartment Vc for these doses was ﬁxed
at 0.05 L/kg. The dots are simulated data and the solid curves are
obtained by ﬁtting the model sketched in Fig. 2 to the data. Estimates
are given in Table 2
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Fig. 4 Left semi-logarithmic graphs of simulated plasma concentra-
tions of L (red discs) and R (blue squares) versus time (Data set (II))
and on the right the same, but also semi-logarithmic graphs of RL
(green triangles) (Data set (III)), taken after administration of four
rapid intravenous injections D of 1.5, 5, 15 and 45 mg/kg, respec-
tively. Vc for these doses was ﬁxed at 0.05 L/kg. The dots are
simulated data and the solid curves are obtained by ﬁtting the model
sketched in Fig. 2 to the data. Estimates are given in Table 2
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values they should have.
Dataset I is made up from simulated concentration–time
proﬁles covering ﬁve orders of magnitude in concentration
range and from 0 to 500 h. Dataset II contains the same
simulated ligand (L) proﬁles as in dataset I as well as target
(R) concentration–time proﬁles obtained at each dose level.
Dataset III includes dataset II but is enriched by four
simulated time-courses of the ligand–target complex (LR)
as well.
The four doses are D = 1.5, 5, 15 and 45 mg/kg. The
volume Vc of the central compartment being 0.05 L/kg, this
yields the following initial ligand concentrations L0 = D/
Vc = 30, 100, 300 and 900 mg/L.
The parameter values given in Table 1 yield the fol-
lowing values for the dissociation constant Kd and the
constant Km related to Kd:
Kd ¼
koff
kon
¼ 0:011mg/L ð7Þ
and
Km ¼
koff þ keðRLÞ
kon
¼ 0:044mg/L ð8Þ
Here, Kd is a measure of afﬁnity between drug (ligand) and
target, whereas Km is more of a conglomerate of afﬁnity
(Kd) and irreversible elimination of the ligand–target
complex (ke(RL)) and used for comparisons to the Michae-
lis–Menten parameter KM of regression model Eq. (45).
Unless the removal of the ligand–target complex is fully
understood, one should be careful about the interpretation
of an apparent Km-value. Km can be very different from the
afﬁnity Kd. Here, solid biomarker (physiological or disease
markers) data on effective plasma concentrations may be a
practical guidance.
Summarizing we may conclude that:
• Dataset I—which involves L—allows the prediction of
robust ligand concentration–time proﬁles within the
suggested concentration and time frame. We see that if
only ligand data are available, the majority of param-
eters except for kon, koff and ke(RL) are estimated with
high precision. The latter three parameters are still
highly dependent on information about the time courses
of either target and/or complex. Since kkon, koff and
ke(RL) have low precision (high CV%) we would
discourage the use of these parameters for the predic-
tion of tentative target and complex concentrations.
• Dataset II—which involves L and R—still gives good
precision in all parameters except koff and ke(RL), which
will also be highly correlated. Since we also have
experimental data of the target we encourage the use of
this model for interpolation of target concentration–
time courses, but not for concentration–time courses of
the complex.
• Dataset III—which includes L and R,a sw e l la sRL—
gives high precision inall parameters. Since we alsohave
measured the complex concentration–time course with
highprecisionweobtainedkoffandke(RL)valueswithhigh
precision. We doubt that the practical experimental
situation can get very much better than this latter case
where we have simultaneous concentration–time courses
ofL, RandRLwithlittleexperimentalerrorduetobiology
andbio-analyticalmethods.DatasetIIIisanidealcase;the
true experimental situation seldom gets better.
We also doubt the practical value of regressing too
elaborate models to data. Models that capture the overall
trend nicely but result in parameters with low precision and
biased estimates may be of little value.
The volume of the central compartment Vc ought to fall
somewhereintheneighbourhoodoftheplasmawatervolume
(0.05 L/kg) for large molecules in general and antibodies in
particular.Inourownexperienceofantibodyprojectsthishas
been the case when data contained an acceptable granularity
within the ﬁrst couple of hours after the injection of the test
compound. Therefore we assumed Vc to be a constant term
(0.05L/kg)inthisanalysisandnotpartofthelistofparameters
to be estimated. We think this increases the robustness of the
estimation procedure and is biologically viable.
Critical features of the graphs
The graphs in Figs. 3 and 4 exhibit certain characteristic
features and so reveal typical properties of the dynamics of
the TMDD system.
(a) Initially all the ligand graphs in Fig. 3 exhibit a rapid
drop which increases in relative sense as the ligand
dose decreases. Over this initial period, which we
refer to as Phase A, (cf. Fig. 1), R(t) exhibits a steep
drop that becomes deeper as the drug dose increases.
(b) After the brief initial adjustment period, the graphs
for large doses reveal linear ﬁrst order kinetics over a
Table 2 Final parameter estimates and their relative standard devi-
ation (CV%) on the basis of the three datasets
Symbol Unit I (L)I I ( L & R) III (L & R & RL)
Vt L/kg 0.101 (2) 0.100 (2) 0.100 (1)
Cld (L/kg)/h 0.003 (4) 0.003 (3) 0.003 (3)
Cl(L) (L/kg)/h 0.001 (1) 0.001 (1) 0.001 (1)
kon (mg/L)
-1/h 0.099 (17) 0.092 (2) 0.096 (1)
koff 1/h 0.001 (27) 0.001 (13) 0.001 (3)
kout 1/h 0.009 (6) 0.009 (2) 0.009 (2)
ke(RL) 1/h 0.002 (27) 0.002 (23) 0.002 (2)
R0 mg/L 12 (4) 12 (1) 12 (1)
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123period of time (Phase B) that shrinks as the drug dose
decreases. At the lowest dose the linear period has
vanished and the graph exhibits nonlinear kinetics.
(c) For the larger doses, there is an upward shift of the
linear phase that appears to be linearly related to the
ligand dose; the slope of this linear phase appears to
be dose-independent.
(d) Thepointofinﬂectioninthelog(L)versustimecurve—
the middle of Phase C—which we observe in the
graphs for L0 = 100 and 300, moves to the right as the
initialdoseincreases,butstaysatthesamelevel.Thisis
clearlyseeninFig. 3inwhichthebaselinevalueR0and
the value of Kd and Km are also shown.
(e) For the lower doses we see that the log(L) versus time
curve eventually becomes linear again, with a slope
that is markedly smaller than it was in the nonlinear
Phase C that preceded it. This part of the graph
corresponds to Phase D in Fig. 1.
Summarising, in the ligand graphs of Fig. 3 we see for
the higher drug doses the different phases A–D that were
pointed out in Fig. 1. In the following analysis we explain
these features and quantify them in that, for instance, we
present estimates for the upward shift referred to in (c) and
the right-ward shift of the inﬂection point alluded to in (d).
Dynamics after a bolus administration
Here we assume that ligand is supplied through an intra-
venous bolus administration and that there is no infusion,
i.e., kf = 0. Thus, we focus on the system
dL
dt ¼  konL   R þ koffRL   keðLÞL
dR
dt ¼ kin   koutR   konL   R þ koffRL
dRL
dt ¼ konL   R  ð koff þ keðRLÞÞRL
8
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In order to obtain a ﬁrst impression of typical concentration
versus time courses for the three compounds, we carry out
a few simulations of the system (9). We then present a
mathematical analysis in which we delineate and discuss
the four phases A, B, C and D in the characteristic ligand
versus time graph shown in Fig. 1.
Simulations
We use the same initial doses as in the case study, i.e., the
initial ligand concentrations are L0 = 30, 100, 300 and
900 mg/L. The parameter values are given in Table 3,
which is the same as Table 1, except that (i) the parameters
VT and Cld are absent because the tissue compartment has
been taken out and (ii) the elimination rate has been
reduced to ke(L) = 0.0015 h
-1 so that the different phases
in the ligand versus time graphs can be distinguished more
clearly.
In Fig. 5 we show three ligand versus time graphs. In the
ﬁgure on the left, L is given on a logarithmic scale and in
the two ﬁgures on the right L is given on a linear scale, with
the one on the right a blow-up of the initial behaviour when
L0 = 900 mg/L.
Table 3 Parameter estimates used for demonstrating the dynamics of
L, R and RL after bolus and constant-rate infusion regimens of L
Symbol Unit Value
ke(L) 1/h 0.0015
kon (mg/L)
-1/h 0.091
koff 1/h 0.001
kin (mg/L)/h 0.11
kout 1/h 0.0089
ke(RL) 1/h 0.003
R0 mg/L 12
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Fig. 5 Graphs of L versus time on semi-logarithmic scale (left), on a
linear scale (middle) and a close up (right), for doses resulting in
initial ligand concentrations L0 = 30, 100, 300, 900 mg/L and
parameters listed in Table 3. In addition, R(0) = R0 and RL(0) = 0.
The dashed lines indicate the target baseline level R0, and the
dissociation constant Kd
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of Fig. 5 exhibit the characteristic shape shown in Fig. 1.
They consist of the following segments:
(a) A rapid initial adjustment (see the blow-up on the
right).
(b) A ﬁrst linear phase with a slope which is independent
of the dose, and which shifts upwards as the drug dose
increases.
(c) A transition phase which shifts to the right as the drug
dose increases, but maintains its level.
(d) A ﬁnal linear terminal phase with a slope kz that is
again independent of the drug dose. For the parameter
values of Table 3 we ﬁnd that kz & ke(RL) = 0.003.
Since in Figs. 3 and 4 the time was restricted to 500 h, the
terminal phase (D) has only just begun for the lowest dose,
and not even started for the higher doses.
In Fig. 6 we present the receptor dynamics: concen-
tration versus time proﬁles for, respectively, R, RL and Rtot
when L0[R0. Whereas in [17] it was assumed that
kout = ke(RL), and hence the receptor pool was constant
(Rtot : R0), for the parameters in Table 3 we have
kout[ke(RL), so that Rtot is no longer constant.
We make the following observations:
(i) The total amount of target Rtot(t)—free and bound to
ligand—increases from its initial value R0 = 12 to a maxi-
mum value R*, and then drops off again towards its baseline
value R0. A similar observation was made in [15, 22].
We shall prove that
R  ¼
kin
keðRLÞ
ð10Þ
Thus, if ke(RL)\kout, as is the case with the parameter
values of Table 3, then R*[R0 and the total target pool
increases before it returns to the baseline value R0.
Alternatively, if ke(RL)[kout, then R*\R0 and we
show that the total target pool ﬁrst decreases before it
returns to the baseline value R0.
Finally, if ke(RL) = kout, then Rtot(t) = R0 for all t C 0
[3, 17].
(ii) As the drug dose increases, R(t) & 0 for an
increasing time interval and the graphs of RL(t) and
Rtot(t) trace—for the same increasing time interval—a
common curve C in the (t, Rtot)-plane (cf. Fig. 9). This
curve C is monotonically increasing and tends to the
limit R* as t !1 : If ke(RL)[kout, we show that an
analogous phenomenon occurs along a curve C; which
still tends to R*, but is now decreasing.
In Fig. 7 we present graphs of R - R0, RL and Rtot - R0
on a logarithmic scale. We note two conspicuous features:
(i) The three graphs exhibit a kink (a sharp angle) which
shifts to the right (increasing time) as the drug dose
increases.
(ii) R(t) - R0 tends to zero as t !1in a bi-exponential
manner, whilst RL(t) and Rtot(t) - R0 converge to zero
in a mono-exponential way.
Low dose graphs
We conclude these simulations with a comparison of high-
dose and low-dose graphs. We do this by adding simula-
tions for initial ligand concentrations which are smaller
than R0. Speciﬁcally, we add the values L0 = 0.3, 1, 3 and
10 mg/L to the graphs shown in Figs. 5 and 6.
Figure 8 shows simulations of the ligand, target and
complex concentration–time courses after eight different
intravenous bolus doses. The initial drop will be difﬁcult to
capture unless that is taken care of experimentally within
the very ﬁrst minutes or so when the second-order process
occurs. We see that in the low-dose graphs (L0\R0) the
signature shape of Fig. 1 is no longer present. Instead, as L0
decreases, the ligand curves become increasingly
bi-exponential, and condensed into an apparent mono-
exponential decline. Still the terminal slope after the
highest and the lowest dose are the same.
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Fig. 6 Graphs of R (left), RL (middle) and Rtot (right) versus time for L0 = 30, 100, 300, 900 mg/L and parameters given in Table 3, whilst
R(0) = R0 and RL(0) = 0. The dashed line indicates the target baseline level R0 and the dotted line the level R*
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123As the ligand doses decrease, the target proﬁle becomes
less affected in terms of intensity (depth) and duration
below the baseline concentration. In fact, one can show that
if R(0) = R0 and RL(0) = 0, then
R0
1 þ
kon
kin
L0
R0
\RðtÞ\R0 1 þ
koff
kout
L0
R0
  
for0\t\1ð 11Þ
The proof of this upper and lower bound is given in
Appendix 3. It is immediately clear that when L0 ? 0 the
upper as well as the lower bound converges to R0.
Therefore, we may conclude that for every t[0,
RðtÞ!R0 asL0 ! 0 ð12Þ
When we replace R(t)b yR0 in the system (9) the resulting
system is linear, involving only Land RL. This explains the bi-
linearcharacterofthelog(L)versustimegraphs(seealso[17]).
Mathematical analysis
We successively describe the dynamics in the four phases:
A–D. Throughout we assume that the ligand has large
afﬁnity for the receptor, that the elimination rates are
comparable, and that the bolus dose is not too small.
Speciﬁcally we assume:
A:edef
=
Kd
R0
  1; B:
keðLÞ
koff
;
keðRLÞ
koff
;
kout
koff
\M;
C:L0 [R0 ð13Þ
where M is a constant which is not too large, i.e., eM   1:
These three assumptions were inspired by the parameter val-
uesgiveninTable 3andtheinitialvaluesofLandR.Weal so
mention a similar model used for the study of Interferon-b 1a
in humans [23] ﬁtted with comparable parameter values.
Phase A Ligand, receptor and receptor–ligand complex
quickly reach Plateau values (L;R;RL) (see the right graph
of Fig. 5). Since L0[R0 by Assumption B, the supply of
free receptor is quickly exhausted, so that these plateau
values are approximately given by
L ¼ L0   R0; R ¼ 0; RL ¼ R0 ð14Þ
Note that this is conﬁrmed by the initial portion of the
graph of L(t) shown in Fig. 5: we see that L drops by
Fig. 7 Graphs of R0 - R (left), RL (middle) and Rtot - R0 (right)
versus time on a semi-logarithmic scale for L(0) = 30, 100, 300,
900 mg/L and R(0) = R0 and RL(0) = 0 mg/L. The parameters are
listed in Table 3. In the middle ﬁgure, the dashed line indicates the
baseline R0 and the dotted line the level R*. In the right ﬁgure the
dotted line indicates R* - R0
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Fig. 8 Graphs of L on a semi-logarithmic scale (left) and R (middle)
and RL (right) on a linear scale versus time for L(0) = 0.3, 1, 3, 10, 30,
100, 300, 900 mg/L and R(0) = R0 and RL(0) = 0. The parameters
are listed in Table 3. The dashed lines indicate the baseline R0 and
Kd, and the dotted line the level R*
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123approximately R0 over a time span of about 0.04 h. In
Appendix 2 we give details of the dynamics in this initial
phase and the approach to the plateau values. We show that
it takes place over a time interval (0, T1), where
1
T1 ¼ O
1
konðL0   R0Þ
  
askon !1 ð 15Þ
When L0 = 900 mg/L this yields a half-life t1/2 of about
0.01 h, in agreement with what is shown in Fig. 5.F o ra
detailed study of Phase A we refer to [17] and to Aston
et al. [24].
Phase B Over the subsequent time span when L(t)  
Kd, say over the interval T1\t\T2, the three compounds
are in quasi-equilibrium. This means that R, RL and
Rtot = R ? RL are—approximately—related to L through
the expressions:
RL ¼ Rtot
L
L þ Kd
and R ¼ Rtot
Kd
L þ Kd
fort[T1
ð16Þ
Since in this phase L(t)   Kd, they may actually be
approximated by the simpler expressions
RL ¼ Rtot and R ¼ 0 forT1\t\T2 ð17Þ
With these equalities, the system (4) can be reduced to the
simpler form
dLtot
dt ¼  keðLÞL   keðRLÞRtot
dRtot
dt ¼ kin   keðRLÞRtot
8
<
:
T1\t\T2 ð18Þ
Note that for Rtot we have obtained a simple indirect
response equation (see also [9]).
Phase C When L(t) = O(Kd), say over the interval
T2\t\T3, the approximation (17) is no longer valid.
Applying a scaling argument appropriate for this regime,
we show in Appendix 5 that to good approximation
RL ¼ Rtot
L
L þ Kd
and R ¼ Rtot
Kd
L þ Kd
for
T2\t\T3
ð19Þ
so that in this phase the rapid binding assumption is
approximately satisﬁed [18].
Phase D When L(t)   Kd, i.e., beyond T3, the ligand
concentration is so small that the dynamics is linear again.
The critical times T1, T2 and T3 provide a natural divi-
sion of the dynamics in four phases: A, B, C and D, as was
done in Fig. 1.I nPhase A (0\t\T1), ligand, receptor
and complex reach quasi-equilibrium, in Phase B
(T1\t\T2), the bulk of the ligand is eliminated from the
system while most of the receptor is bound to ligand and in
quasi-equilibrium. Phase C (T2\t\T3) is a nonlinear
transitional phase in which L exhibits a steep drop, and
ﬁnally, in Phase D (T3\t\1) the three compounds
converge linearly towards their baseline values.
Receptor graphs: Phase B
In Phase B, which extends over the interval T1\t\T2,
the system (18) holds. Since the second equation only
involves Rtot as a dependent variable, it can be solved
explicitly to yield
RtotðtÞ¼R  þ RtotðT1Þ R  fg e keðRLÞðt T1Þ forT1\t\T2
Because T1 is small by the estimate (15), it follows from the
system (4) and the initial conditions that Rtot(T1) & R0. Thus,
togoodapproximation,we mayputT1 = 0an dRtot(0) = R0,
and so simplify the above expression for Rtot(t)t o
RtotðtÞ¼R  þ R0   R  ðÞ e keðRLÞt for0\t\T2 ð20Þ
where we recall from Eq. (10) that R* = kin/ke(RL). Plainly,
if T2 were inﬁnite, then
RtotðtÞ!R  ast !1 ð 21Þ
We denote the graph of the function Rtot(t)b yC:
In Fig. 9 we see how for the different drug doses, the
simulations of Rtot(t) follow the graph C up till some time,
when they suddenly depart from C:
Remark We recall from the approximation (17) that R(t)
& 0 for T1\t\T2 and hence that RL(t) & Rtot in this
phase of the dynamics, as we see conﬁrmed in Fig. 6.
We conclude with a bound of the target pool. It is evi-
dent from the receptor graphs in Figs. 6, 7, 8 and 9 that for
the data of the case study, the total receptor concentration
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Fig. 9 Simulated graphs of Rtot(t) for the initial ligand concentrations
L0 = 30, 100, 300, 900 mg/L and data from Table 3, together with the
curve C (dashed) given by the analytic expression (20). Notice how,
as L0 increases, the graph of Rtot(t) follows C over a longer period of
time
1 For the deﬁnition of the O-symbol, see Appendix 1.
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123Rtot is not constant. However, it remains bounded for all
time and does not keep on growing. In fact it is possible to
prove the boundedness of Rtot under very general condi-
tions on the data, and actually obtain a sharp value for the
upper bound. Speciﬁcally, we have
RtotðtÞ 
R0 if keðRLÞ  kout
R  if keðRLÞ  kout
 
fort 0: ð22Þ
The proof is given in Appendix 3.
Ligand graphs: Phase B
Over the interval (T1,T2) in which it is assumed that L  
Kd, we can use (17) to simplify the ﬁrst equation from the
system (18) as follows:
d
dt
L þ Rtot ðÞ ¼   keðLÞL   keðRLÞRtot forT1\t\T2 ð23Þ
Subtracting the second equation of (18)f r o m( 23)w eo b t a i n
dL
dt
¼  keðLÞL   kin forT1\t\T2 ð24Þ
Equation (24), together with the initial value LðT1Þ¼L;
can be solved explicitly. In Appendix 4 we show that the
solution is given by
LapproxðtÞ¼ L þ
kin
keðLÞ
  
e keðLÞt  
kin
keðLÞ
for0\t\T2
ð25Þ
where T1, being small, has been put equal to zero. We
recall from Eq. (14) that L   L0   R0:
In Fig. 10 we compare the numerically computed ligand
versus time graphs L(t) with the analytic approximation
Lapprox(t) given by the expression (25). It is evident that the
two curves are very close until L has become so small that
it is comparable to Kd, i.e., until the end of Phase B, where
the nonlinearity pitches in.
Since the function Lapprox(t) is decreasing, Lapprox(0)[0
and Lapprox(t) ? - kin/ke(L)\0a st !1 ; it follows that
there exists a unique time T
*[0 at which Lapprox(t) van-
ishes. We readily conclude from the deﬁnition of Lapprox(t)
that T
* is given by
T  ¼
1
keðLÞ
log
keðLÞ
kin
ðL0   R0Þþ1
  
ð26Þ
Remark It is clear from Eq. (24) that for larger values of
L0, we may estimate ke(L) from the slope of log(L) and in
Fig. 10 we see that T
* yields a good estimate for T2, the end
of Phase B. Information about ke(L) and T
* combined yields
an estimate for kin from the expression
kin ¼
keðLÞ
ekeðLÞT    1
ðL0   R0Þð 27Þ
which can be derived from (26).
When Kd is very small, as is the case for the parameter
values of Table 1, the approximation Lapprox(t) given by
(25) is valid for most of the range of L and can therefore be
used to obtain an estimate for the area under the ligand
curve AULC. An elementary computation yields
AULCðDÞ¼
Z 1
0
Lðt;L0Þdt
 
Z T 
0
Lapproxðt;L0Þdt
¼
D
keðLÞVc
1   l   jllog
1 þð j   1Þl
jl
     
;
l ¼
R0
L0
; j ¼
kout
keðLÞ
ð28Þ
Details are given in Appendix 4. This expression for AUCL
yields for the clearance
CLðDÞ¼
D
AULCðDÞ
  keðLÞVc 1   l   jllog
1 þð j   1Þl
jl
       1
ð29Þ
It is interesting to compare these approximate
expressions for AUCL and CL with the corresponding
expressions for mono-exponential ligand elimination. They
are, respectively, D/(ke(L)Vc) and ke(L)Vc. Thus we see that
they are related by a factor which only depends on two
dimensionless critical numbers:
(i) the ratio l of R0 and L0 and
(ii) the ratio j of the direct elimination rates of receptor,
kout, and ligand, ke(L).
Fig. 10 Graphs of L versus time on a semi-logarithmic scale for data
as in Fig. 5. The dashed curves are the analytic approximations for
the different drug doses, given by Eq. (25). Recall from Eq. (7) that
Kd = 0.011 mg/L
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123Since l? 0a sL0 !1 ; we conclude from (28) and (29)
that
AULCðDÞ 
D
keðLÞVc
and CLðDÞ!keðLÞVc
asD !1
Ligand and receptor graphs: Phases C and D
In Phase C the ligand concentration L has become com-
parable to Kd and, as is shown in Appendix 5, we have to
good approximation
L   R ¼ Kd   RL and RL ¼ Rtot
L
L þ Kd
ð30Þ
This suggests using a different scaling of L. For deﬁnite-
ness we assume that Phase C comprises the time interval in
which L drops from 10 9 Kd to 0.1 9 Kd, and denote the
times that L(t) reaches 10 9 Kd and 0.1 9 Kd by, respec-
tively, T2 and T3. Thus, L(T2) = 10 9 Kd and L(T3) =
0.1 9 Kd.
In Phase C we use the approximation (30) in the ligand
conservation law in (4):
d
dt
L þ Rtot
L
L þ Kd
  
¼  keðLÞL   keðRLÞRtot
L
L þ Kd
ð31Þ
We now introduce Kd, which—like L, R and RL, has the
dimension of a concentration—as a reference variable for
L, and introduce the dimensionless variables
uðtÞ¼
LðtÞ
Kd
and vðtÞ¼
RtotðtÞ
R0
ð32Þ
Using these variables in Eq. (31) we obtain
d
dt
eu þ v
u
u þ 1
  
¼  keðLÞeu   keðRLÞv
u
u þ 1
; e ¼
Kd
R0
Since e   1; and v = O(1) (cf. Fig. 6), we may neglect the
term eu in the left- and the right-hand side of this equation
and so obtain
d
dt
v
u
u þ 1
  
¼  keðRLÞv
u
u þ 1
ð33Þ
In the simulations shown in Figs. 5 and 6 we see that in
Phase C, L drops rapidly from O(10 9 Kd)t oO(0.1 9 Kd),
i.e., by a factor 100, whilst Rtot stays relatively close to R*
and changes by no more than a factor 1/7 & 0.15. This
suggests making the following assumption:
Assumption Rtot(t) & R* or v(t) & R*/R0 in Phase C.
Thanks to this assumption we may view v as a constant,
which we may divide out and thus eliminate from the
equation. We end up with a simple nonlinear equation for
u, which is valid in Phase C:
du
dt
¼  keðRLÞuðu þ 1Þ forT2\t\T3 ð34Þ
Since LðT2Þ¼10   Kd; it follows that u(T2) = 10. Equation
(34) can be solved explicitly and we ﬁnd for its solution:
uðtÞ¼
Ae keðRLÞðt T2Þ
1   Ae keðRLÞðt T2Þ fort T2;
A ¼
uðT2Þ
1 þ uðT2Þ
¼
10
11
¼ 0:91
ð35Þ
Returning to the original variables we obtain for the large
time behaviour
logfLðtÞg  logðKdÞþlogðAÞ keðRLÞðt   T2Þ ast !1
ð36Þ
The asymptotic expression (36) yields estimates for
(i) the terminal slope kz
TMDD (ke(RL));
(ii) the intercept of the asymptote of log{L(t)} of the
ligand graph in the terminal Phase D with the vertical
line {t = T2}.
The approximate identities in (30) imply that in Phases
C and D, when L = O(Kd), we have to good approximation
dRL
dt
¼  keðRLÞRL ð37Þ
so that
RLðtÞ R e keðRLÞt ð38Þ
This is consistent with the value of kz found for L(t).
We also ﬁnd that to good approximation
dR
dt
¼ kin   koutR ð39Þ
so that
RðtÞ R0ð1   e kouttÞð 40Þ
This conﬁrms what we see in Fig. 7: that for t[T2 the
receptor concentration R(t) tends to R0 in a bi-exponential
manner, in contrast to the way RL(t) tends to zero, which is
mono-exponential.
For completeness we also compute the terminal slope by
meansofastandardanalysisofthefullTMDDsystem.Thisis
doneinAppendix7.Itisfoundthatfortheparametervaluesin
Table 3,theterminalslopekzofallthecompounds,isgiven—
to good approximation—by kz
TMDD = ke(RL).T h i sc o n ﬁ r m s
the limit in (36) and the exponent in (38).
Comparison with Michaelis–Menten kinetics
In many studies involving TMDD, models are employed
that combine linear and saturable Michaelis–Menten type
elimination (e.g. see [14]) of the form
J Pharmacokinet Pharmacodyn (2012) 39:429–451 439
123dL
dt
¼  kL   Vmax
L
L þ KM
ð41Þ
in which k, Vmax and KM are empirical parameters. The
underlying assumption is that the MM-term can replace the
combined ﬁrst and second order processes of buildup and
elimination via the complex in the TMDD model within a
certain ligand concentration range.
In light of (24), ﬁtting the data for large values of the
ligand concentration would yield k = ke(L) and Vmax = kin.
Putting KM = Kd, Eq. (41) then becomes
dL
dt
¼  keðLÞL   kin
L
L þ Kd
ð42Þ
Alternatively, we can take (31) as point of departure.
Following [15] we assume that RtotKd   (Kd ? L)
2. Then
the left hand side of (31) reduces to dL/dt. Assuming that
Rtot & R* and remembering that ke(RL)R* = kin, we may
replace the factor k(e(RL)Rtot in the right hand side of (31)b y
kin and so arrive at (42).
Fitting to data of low ligand concentrations (L   Kd),
Eq. (42) reduces to the linear equation
dL
dt
¼  keðLÞ þ
kin
Kd
  
L ð43Þ
which yields a terminal slope kz
MM given by
k
MM
z ¼ keðLÞ þ
kin
Kd
ð44Þ
This terminal slope is quite different from the value kz
TMDD
obtained in (36) and (38). For the parameter values of
Table 3, we ﬁnd that kz
MM   kz
TMDD.
Thus, the TMDD-model and the Michaelis–Menten
(MM)-model exhibit very different terminal slopes, unless
one also includes a non-speciﬁc peripheral volume distri-
bution term in the MM-model.
Michaelis–Menten model with peripheral compart-
ment. Adding a peripheral compartment to the MM-model
makes it possible to capture the slow terminal elimination
that is typically seen in TMDD data. Figure 11 shows the
regression of a 2-compartment model with parallel linear
(Cl(L)) and Michaelis–Menten (Cl = Vmax/(Lp ? KM))
elimination:
Vc
dLp
dt ¼  ClðLÞLp   CldðLp   LtÞ Vmax
Lp
LpþKM
Vt
dLt
dt ¼ CldðLp   LtÞ
8
<
:
ð45Þ
Fitting this model to the data shown in Fig. 3 results in the
parameter estimates which, together with their precision
(CV%), are given in Table 4.
The reduced model mimics the concentration–time data
for the two highest doses reasonably well, whereas the two
lower doses display systematic deviations between
observed and predicted data.
Since the reduced model has two parallel elimination
pathways (linear and nonlinear) it has the intrinsic capacity
of exhibiting linear ﬁrst-order kinetics at low and at high
concentrations. In the concentration-range in between it
behaves nonlinearly. For higher concentrations the MM-
Table 4 Parameter estimated from ﬁtting the Michaelis–Menten
model (Eq. (45)) to the data shown in Fig. 11. As in the Case Study,
Vc is ﬁxed
Symbol Unit Value CV%
Vc L/kg 0.05 –
Vt L/kg 0.1 10
Cld (L/kg)/h 0.00307 20
Cl(L) (L/kg)/h 0.00090 10
Vmax mg/h 0.0146 40
KM mg/L 3.68 50
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Fig. 11 Fitting the
2-compartment Michaelis–
Menten model (45) to the data
of Fig. 3 which are represented
by the dots. The drawn curves
are predictions of the
Michaelis–Menten model for
the parameter values listed in
Table 4. The dashed line in the
middle of the plot indicates the
estimated value of KM. Notice
how far away it is from the
original value of Km—marked
by the thin drawn line—which
was estimated by the TMDD
model
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123route is saturated and the linear elimination pathway
dominates so that the system behaves linearly.
However, the typical concentration–time pattern for
ligand seen in a true TMDD system (cf. Figs. 5, 8, 10),
cannot be fully described by the parallel linear- and MM-
elimination model. The reduced model displays typical bi-
exponential decline (which is expected from a two-com-
partment model) at lower concentrations. That is generally
not the case with the full TMDD model.
A clear distinction of the two models occurs initially,
immediately after dosing (Phase A), when the second-order
reaction between ligand and circulating target forms the com-
plex. This process cannot be captured by the reduced model,
which may cause biased estimates (too large) of the central
volume.
In Table 5 we summarise these results. It shows that the
MM-models (41) and (45) may be ﬁtted successfully to the
ﬁrst part of the ligand versus time graph, although they
miss the initial drop in Phase A. They catch the ﬁrst part of
Phase C, but the ﬁrst model fails to catch the second part,
where the graph joins up with the terminal Phase D. The
second MM-model is an improvement, but still shows
signiﬁcant deviations for lower ligand-concentrations.
In this table, a plus (?) means that the corresponding
phase can be adequately explained, whilst a minus (-)
means that it cannot.
Constant rate drug infusion
We assume that the drug is administered through a constant-
rate infusion over a ﬁnite period of time, and we are inter-
ested in elucidating which parameters are critical in deter-
mining the time to steady state, the extent of steady state
ligand, target and ligand–target complex concentrations and
the dynamics after washout. Assuming that the infusion rate
reaches its constant value kf in a negligible amount of time
and that washout at time twashout is also instantaneous, we
consider the following variant of the system (1):
dL
dt ¼kfHðtwashout tÞ konL RþkoffRL keðLÞL
dR
dt ¼kin koutR konL RþkoffRL
dRL
dt ¼konL R ðkoffþkeðRLÞÞRL
8
> > > <
> > > :
ð46Þ
in which H(t) denotes the Heaviside function: H(t) = 0i f
t\0a n dH(t) = 1i ft[0. Thus, H(twashout - t) = 1i f
t\twashoutandH(twashout - t) = 0ift[twashout.Weassume
that initially there is no ligand in the system, i.e., L0 = 0.
When the infusion lasts long enough, i.e., when twashout
is large enough, the concentrations will converge towards
their steady state values Lss, Rss and RLss. Then, at wash-
out, they will return to their pre-infusion values: L = 0,
R = R0 and RL = 0.
We ﬁrst derive expressions for the steady state values.
Then we carry out a series of simulations subject to the
same assumptions as those made in (13), except that we
replace Assumption C by
C  :LssðkfÞ[R0 ð13 Þ
As we shall see, Lss is an increasing function of kf, so that
we require here that kf does not drop below a threshold
value for which Lss(kf) = R0. We discuss features of the
dynamics exhibited in these simulations, especially the
time to steady state after onset of infusion, and after
washout.
Steady state concentrations of L, R and RL
For the steady state concentrations Lss, Rss and RLss of the
system (46) we ﬁnd the following expressions. For the
ligand–receptor concentration we obtain
RLss ¼
1
2keðRLÞ
kf þ kin þ q  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðkf þ kin þ qÞ
2   4kfkin
q   
;
ð47Þ
in which q = (ke(L)/ke(RL))koutKm. In light of the
conservation laws for ligand and target, we then obtain
for the ligand
Lss ¼
1
keðLÞ
ðkf   keðRLÞRLssÞð 48Þ
and for the target,
Rss ¼
1
kout
ðkin   keðRLÞRLssÞð 49Þ
The expressions (47)–(49) are derived in Appendix 6.
The formula (48) for the ligand shows that Lss will be
smaller than expected from the ratio of ligand infusion rate-
to-clearance (InL/Cl(L) = kf/ke(L)), due to the removal of
ligand as part of the complex RLss. The same reasoning
may be used to explain why the circulating target con-
centration Rss given by (49) is smaller than the baseline
concentration R0 = kin/kout. Due to the removal of target by
means of the complex, the target concentration Rss will
drop further as the infusion rate increases and RLss
increases accordingly (cf. Eq. (49)).
Table 5 Phases that can be explained by the two MM-models and the
TMDD-model
Phase MM-model (41) MM-model (45) TMDD-model (9)
A --?
B ???
C ?/-? ?
D --?
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123Figure 12 shows graphs of Lss, Rss and RLss as functions
of the infusion rate kf for the parameter values of Table 3.
Note that at large infusion rates, Lss increases approxi-
mately linearly, except for a downward shift. Indeed, this is
conﬁrmed analytically: by expanding the expression (48)
for large values of kf, we obtain
LssðkfÞ 
1
keðLÞ
ðkf   kinÞ askf !1 ð 50Þ
The reason is that for large infusions, elimination of ligand
occurs primarily via the extra-target elimination route
(ke(L)). For small infusion rates the removal of ligand is also
seen to be ﬁrst order, but clearly at a much lower rate.
In Fig. 12 the receptor concentration Rss is seen to
decrease and the complex concentration RLss is seen
to increase as kf increases. However, it is interesting to
observe that RLss reaches an upper bound in spite of
increasing levels of kf. This is also conﬁrmed analytically:
letting kf tend to inﬁnity in (47) and (49) we obtain the
limits
RssðkfÞ!0 and RLssðkfÞ!R  askf !1 ð 51Þ
Thus, the upper bound is found to be R* = kin/ke(RL).
It is interesting to note that when plotted on a loga-
rithmic scale, the elimination of target mirrors the elimi-
nation of ligand for larger values of the infusion rate (cf.
Fig. 12 on the right). This can be understood from the
relation
konLss   Rss  ð koff þ keðRLÞÞRLss ¼ 0 ð52Þ
obtained from (46). When we divide Eq. (52)b ykon and
take the logarithm, we obtain
logðLssÞþlogðRssÞ¼logðKmÞþlogðRLssÞ
For larger values of kf we have RLss & R* (cf. (51)), and
hence
logðLssÞþlogðRssÞ logðKmÞþlogðR Þð 53Þ
which establishes the symmetry which is evident in the
graphs for Lss and Rss shown on the right in Fig. 12.
Using the parameter values in Table 3, we obtain 1/
ke(L) = 667, kin/ke(L) = 73, R* = kin/ke(RL) = 36.7 and
log(Km) ? log(R*) = 0.45. We see that these values are
conﬁrmed by the numerically obtained graphs shown in
Fig. 12.
We note that the expressions (47)–(49) show that the
steady state concentrations do not depend on the on- and
off rates kon and koff individually, but only as part of the
constant Km.
Simulations
We show simulations of concentrationversus time graphsof
the system (46) when drug is supplied through a constant-
rate infusion over a period of 5000 h. Four infusion rates are
considered: kf = 0.12, 0.18, 0.30 and 0.54 (mg/L)/h. In
Fig. 13 we show ligand graphs, on a linear and on a semi-
logarithmic scale, and in Figs. 14 and 15 we show graphs
oftheconcentrationofR, RLandRtot, ﬁrstonalinearscale
a n dt h e na l s oo nal o g a r i t h m i cs c a l e .I ne a c ho ft h e s eﬁ g -
ures we include the build-up phase as well as the washout
phase.
In Fig. 13 we see that for larger values of kf the time-to-
steady state of the ligand L is more or less independent of
the infusion rate. The amounts of ligand are now so large
that the receptor is quickly saturated and ceases to play an
important role in the dynamics. What remains is the linear
clearance of ligand, so that the ligand dynamics is descri-
bed to good approximation by the equation
dL
dt
¼ kf   keðLÞL   kin ð54Þ
which can be solved explicitly. Evidently
LðtÞ!
1
keðLÞ
ðkf   kinÞ ast !1 ð 55Þ
which is consistent with (50) and
t1=2 ¼
logð2Þ
keðLÞ
ð56Þ
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Fig. 12 The steady state
concentrations Lss, Rss and RLss
graphed versus the infusion rate
kf, on a linear scale (left) and on
a log-log scale (right) for
parameter values taken from
Table 3
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&1850 h for the parameter values given in Table 3.
The washout dynamics is very similar to the dynamics
after a bolus dose, as described before: Phase A (0,T1) now
covers the infusion period so that T1 coincides here with
the time of washout. Phases B–D are plainly evident in the
post-washout dynamics.
The dynamics of the receptor R and the receptor–ligand
complexRLareshowninFigs. 14and15.AsinPhaseAinthe
bolus administration, the pre-dose receptor pool (R0)q u i c k l y
bindstotheligand.Weseethatthespeedofreceptordepletion
increases with increasing infusion rate kf,c o n s i s t e n tw i t ht h e
half-life estimate (15) after a bolus administration.
In due course, additional receptor is formed, albeit more
slowly—and binds immediately to the ligand—resulting in
an increase of RL as was observed after a bolus dose (see
also Fig. 6). The dynamics is very similar—compare Eq.
(20)—and
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L)/h and twashout = 5000 h. The
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Fig. 14 Concentration proﬁles of R, RL and Rtot versus time caused
by a constant rate infusion of 5000 h and infusion rates of kf = 0.12,
0.18, 0.30 and 0.54 (mg/L)/h. The parameter values are taken from
Table 3. Note that the time to full depletion of target R decreases as
the infusion rate kf of ligand increases
Fig. 15 Graphs of R0 - R, RL and Rtot - R0 versus time when kf=
0.12, 0.18, 0.30 and 0.54 (mg/L)/h. The parameter values are taken
from Table 3. Note that the convergence of target R to R0 is bi-
exponential and that the decline of complex RL to zero, and the
convergence of total target Rtot to R0 are mono-exponential
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logð2Þ
keðRLÞ
ð57Þ
This results in a time-to-steady-state of 3–4 9 t1/2 is &924
h (cf. Table 3), which we see conﬁrmed in Figs. 14 and 15.
Eventually RL(t) levels off at the steady state value
RLss, which is close to R* for the larger infusion rates (cf.
Eq. (51)).
After washout, when kf is large, R(t) & 0 and RL(t) &
R* for a while before they abruptly return to their baseline
values. It is evident from Fig. 15 that, as in Fig. 7, initially
the slope of log(R0 - R) is steeper than that of log(RL).
This is in agreement with the analysis presented in
Appendix 5, where it is shown that over that period
the half-lives of R(t) - R0 and RL(t) are, respectively,
O(1/kout) and O(1/ke(RL).
Discussion and conclusion
We have shown how the concentration proﬁle of ligand,
receptor and ligand–receptor complex in the TMDD model
can be divided into four different phases and how for each
of these phases closed-form approximations can be
derived. Inspired by a speciﬁc case study, the following
assumptions were made about the parameter values (see
also (13) and (13*)):
e ¼
Kd
R0
  1; a ¼
keðLÞ
koff
\M; b ¼
kout
koff
\M;
c ¼
keðRLÞ
koff
\M
ð58Þ
for some moderate constant M[0, and L0[R0.
When ligand is administered through a bolus dose,
L0[R0, and the conditions in (58) are satisﬁed, four
phases can be distinguished in the ligand elimination
graph: a brief initial Phase A, a slow linear Phase B,a
rapid nonlinear Phase C and then again a slow linear ter-
minal Phase D (cf. Fig. 1). Thanks to accurate analytical
approximations for these four phases as shown in the Eqs.
(14) for Phase A,( 20), (25)–(27) for Phase B,( 36) for
Phase C and (38) and (40) for Phase D, we may extract
information about the model parameters.
In Table 6 we list the parameter values which play a
central role in the different phases of TMDD graphs. In
Phase A : the drop (R0) and the duration (O(1/(konL0))), in
Phase B : the slope (ke(L)) and the receptor input (kin), in
Phase C : the depth (Kd) and in Phase D : the terminal
slope (ke(RL)). In brackets we have included the parameters
which can be estimated when results from earlier phases
are used. Thus, since Phase A yields an estimate for
R0 = kin/kout and Phase B an estimate for kin, an estimate
for kout follows.
It should be noted though that estimating R0 may be
difﬁcult, since often there are no data for the ﬁrst phase
because it is over very quickly.
In Fig. 16 we summarise these results and show in the
schematic ligand versus time graph (recall Fig. 1)t h e
parameterswhichmaybeestimatedfromthedifferentphases.
The four phases identiﬁed in the ligand elimination
graph after a bolus administration are reﬂected in the
structure of the receptor versus time graphs (receptor,
receptor–ligand complex, and total amount of receptor).
During Phase A the receptor pool is quickly depleted, and
it remains so during Phase B. Then, during the Phases C
and D it climbs back to the terminal baseline level R0.
The analytic approximations obtained for L, R and Rtot
may be used to verify the validity of the assumptions which
underpin different approximations to the full TMDD model
when the Assumptions A, B and C (or C
*) regarding the
parameters are satisﬁed.
1. The rapid binding model [6, 18], in which it is
assumed that
L   R ¼ KdRL ð59Þ
where Kd is deﬁned in (7). In Phase B, which is
characterised by R(t) & 0, we have dR/dt & 0 so that,
according to the second equation of the system (9), we
have approximately
Table 6 Information contained in the four phases
Phase TMDD-model (9)
AR 0 and kon
Bk e(L), kin (kout)
CK d (koff)
Dk e(RL) (Km)
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Fig. 16 Schematic representation of how the parameters may be
derived from properties of the four phases. In Phase A ligand binds to
the receptor (kon), during Phase B ligand is primarily eliminated
directly (ke(L)); time of termination yields information about kin.I n
Phase C the saturation term is important (Kd), and in Phase D ligand
elimination proceeds mainly though the receptor (ke(RL))
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123D ¼
def L   R   KdRL ¼
kin
kon
ð60Þ
which disagrees with (59).
In contrast, in Phases C and D the identity (59) is satisﬁed
accordingtotheresultsestablishedinAppendix5(cf.(102)),
and Appendix 7 where it was shown that kz = ke(RL).
In Fig. 17 we show how the quantity D ¼ L   R   KdRL
varies with time and how D rapidly jumps from kin/kon down
to zero at the transition of Phases B and C.
2. The quasi-steady-state model [7, 18] in which it is
assumed that
L   R ¼ KmRL ð61Þ
where Km is deﬁned in (8). Evidently, this assumption is
not valid during Phases C and D, but it is during that part
of Phase B in which RL(t) & R*. In that interval dRL/dt &
0 (cf. Fig. 6) and hence, by the third equation of the system
(1), condition (61) is approximately satisﬁed.
Anchored on the data of the Case Study, the analysis in
this paper is based on the Assumptions A, B and C (or C
*).
The question arises whether the characteristic features of
the ligand elimination curves, such as shown in Fig. 1, are
still present when these assumptions are not met.
In general, the behaviour of nonlinear systems such as
(1) is very sensitive to the values of the parameters and
initial data involved. However, a number of features of the
ligand versus time graphs is quite robust in that they may
survive if e.g. Assumption A is not satisﬁed and Kd and R0
are comparable. Thus, the estimate (15) for T1 suggests that
the initial Phase A will remain short relative to typical
times over which the other processes develop when Kd/L0
is small. We refer to [17] and [18] for a detailed analysis of
this situation.
The approximate expressions for L and Rtot in Phase B
(Eqs. (25) and (20)) are still valid provided that R(t) & 0.
This will still be the case when Assumption A is replaced
by Kd   L0 [17, 18].
In contrast, the analysis of the dynamics in Phase C that
is carried out in Appendix 5 depends critically on
Assumption A. It will be interesting to study the dynamics
beyond Phase B when Assumption A does not hold, as it
will be interesting to see how the value of a, b and c affects
the dynamics.
We have selected a set of data (ligand and circulating
target and complex) with low experimental variability,
concentration–time courses at four ligand doses given as
bolus injections, and well-spaced data in time that captures
the necessary phases and shapes of a typical TMDD system.
Based on this approach and the mathematical/analytical
analysis,wecandrawconclusionsabouttheidentiﬁabilityof
themodelparametersandappropriatesystem.Whendataare
less precise and information rich, or, when target and/or
complex are less accessible, the a priori expectations of
parameter accuracy and precision will be lower.
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Appendix 1: Symbols and deﬁnitions
Concentrations and related quantities
L Ligand concentration (mg/L)
R Receptor concentration (mg/L)
RL Receptor–ligand concentration (mg/L)
Ltot Total ligand concentration (L ? RL) (mg/L)
Rtot Total receptor concentration (R ? RL) (mg/L)
L0 Initial ligand concentration (mg/L)
R0 Initial receptor concentration (mg/L)
R* Intermediate steady state receptor concentration
(mg/L)
L Plateau value of the ligand concentration (mg/L)
R Plateau value of the receptor concentration (mg/L)
RL Plateau value of the receptor–ligand
concentration (mg/L)
Lss Steady state ligand concentration (mg/L)
Rss Steady state receptor concentration (mg/L)
RLss Steady state receptor–ligand concentration (mg/L)
Lapprox Approximation of the ligand concentration (mg/L)
AULC Area Under the Ligand Concentration curve (mg/
h/L)
Fig. 17 Evolution of the quantity D ¼ L   R   KdRL with time for
two initial doses L0 = 300 and 900. Parameter values are taken from
Table 1. Note the agreement with the analytical predictions made
above for Phases B, C and D
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123CL Apparent clearance of ligand (L/h)
kz terminal slope (h
-1)
Parameters in the model
InL Infusion rate of ligand (mg/h)
Vc Volume of the central compartment (L)
Vt Volume of the peripheral compartment (L)
Cld Inter-compartmental distribution (L/h)
Cl(L) Direct ligand elimination (L/h)
kf InL/Vc (mg/L/h)
ke(L) First-order elimination rate constant of ligand
(h
-1)
kin Turnover rate of receptor (mg/h)
kout Fractional turnover rate of receptor (h
-1)
kon Second order association rate of ligand to
receptor ((mg/L)
-1/h)
koff First-order dissociation rate of receptor–ligand
complex (h
-1)
ke(RL) First-order elimination rate of receptor–ligand
complex (h
-1)
Kd koff/kon (mg/L)
Km (koff ? ke(RL))/kon (mg/L)
KM Michaelis–Menten constant in Eq. (45) (mg/L)
Vmax Maximum elimination rate in Eq. (45)( m g / k g / h )
T1, T2, T3 Times where the ligand versus time curve
changes qualitatively (h)
T
* Time when Lapprox(t) vanishes (cf. Eqs. (25)
and (26)) (h)
Dimensionless quantities
x, y, zL /L0, R/R0, RL/R0; dimensionless concentrations
x;y;z L=L0;R=R0;RL=R0; dimensionless
concentrations
u, v, wL /Kd, R/R0, RL/R0; dimensionless concentrations
s konR0 t; dimensionless time
e Kd/R0
j kout/ke(L)
l R0/L0 or R0/Lss
a ke(L)/koff
b kout/koff
c ke(RL)/koff
Mathematical deﬁnitions
A ¼
def B The symbol A is deﬁned by the
expression B
f(x) * g(x)a sx ? ? f(x)/g(x)?1a sx? ?
(x ? 0)
f(x) = O(x(x))
as x? ?(0)
There exist constants K[0 and
n[0 such that
|f (x)|\K|x(x)| if x[n (0\
x\n)
Appendix 2: Short time analysis
We present a mathematical analysis for Phase A and show
how ligand, receptor and ligand–receptor complex rapidly
converge to the new Plateau values L;R and RL given in
(14), where we assume that L0[R0.
In order to identify terms in the system (9) which
dominate the dynamics in this initial phase, we deﬁne the
dimensionless concentrations
x ¼
L
L0
; y ¼
R
R0
; z ¼
RL
R0
ð62Þ
and the dimensionless parameter l = R0/L0. Substituting
them into the system (1) we obtain
dx
dt ¼  konR0x   y þ kofflz   keðLÞx
dy
dt ¼ koutð1   yÞ konL0x   y þ koffz
dz
dt ¼ konL0x   y  ð koff þ keðRLÞÞz
8
> > > <
> > > :
ð63Þ
Introducing the dimensionless time s = konR0 t, then
results in the dimensionless system
dx
ds ¼  x   y þ elz   eax
dy
ds ¼ ebð1   yÞ l 1x   y þ ez
dz
ds ¼ l 1x   y   eð1 þ cÞz
8
> > > <
> > > :
ð64Þ
where we have introduced the following dimensionless
constants (see also (58)):
e ¼
Kd
R0
; a ¼
keðLÞ
koff
; b ¼
kout
koff
and c ¼
keðRLÞ
koff
ð65Þ
We multiply the third equation of (64)b yl and add the
resulting equation to the ﬁrst equation to obtain
d
ds
ðx þ lzÞ¼  ea x þ lcz ðÞ ð 66Þ
Similarly, we add the second and the third equation to
obtain
d
ds
ðy þ zÞ¼eb ð1   yÞ cz fg ð 67Þ
Since e   1a n dea   1;eb   1a n dec   1b y
Assumption B (cf. (13)), it follows that to good approximation,
xðsÞþlzðsÞ¼1 and yðsÞþzðsÞ¼1i f es   1
ð68Þ
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z(0) = 0. Note that in light of the deﬁnition of s and e; the
assumption es   1 is equivalent to kofft   1.
Remark These approximate equalities state that the total
amount of ligand (L ? RL) and the total amount of
receptor (R ? RL) in the system remain more or less
constant during this initial phase.
Using the expressions from (68) to eliminate x and y
from the equation for z in (64), we obtain
dz
ds
¼ fðzÞdef
=
1
l
ð1   lzÞð1   zÞð 69Þ
where we have dropped the term elð1 þ cÞz because
elc\ec   1 so that its impact is negligible.
The right hand side of Eq. (69) has two zeros: z = 1a n d
z = 1/l[1. Plainly f(z)[0f o r0B z\1 and for z[1/l,
whereas f(z)\0f o r1\z\1/l.S i n c ez(0) = 0 it follows
thatz(s)increasesandapproachesthelowerzeroz ¼ 1astime
tends to inﬁnity:
zðsÞ!z ¼ 1a s s !1 ð 70Þ
When we linearise Eq. (69)a tz = 1, write zðsÞ¼1 þ fðsÞ
and omit the terms involving f
n for n[1 we obtain the
equation
df
ds
     
z¼1
¼ 
1   l
l
f ð71Þ
Therefore,
s1=2 ¼ lnð2Þ 
l
1   l
¼) t1=2 ¼
lnð2Þ
konðL0   R0Þ
ð72Þ
Thus, for es   1; i.e., for kofft1/2 to be small, as required in
(68),theparametersandtheinitialligandconcentrationneed
to be such that koff/(kon(L0 - R0)   1o rL0 - R0  Kd.
In light of (68), the limit for z(s) obtained in (70) implies
the following limits for x(s) and y(s):
xðsÞ!x ¼
def 1   lz ¼ 1   l and yðsÞ!y ¼
def 1   z ¼ 0
ass !1
ð73Þ
Returning to the original variables and writing L ¼ L0x;
R ¼ R0y and RL ¼ R0z; we conclude that over a time span
of O(1/(kon(L0 - R0)) we have
LðtÞ!L ¼ L0   R0; RðtÞ!R ¼ 0 and
RLðtÞ!RL ¼ R0 ast !1 ð74Þ
Appendix 3: Bounds of the receptor concentration
We establish two a-priori bounds: one for the total receptor
concentration by Rtot = R ? RL and one for the free
receptor concentration R. Both bounds are global in time,
i.e., they hold for all time.
Lemma 1 Suppose that Rtotð0Þ¼R0 ¼
def kin=kout: Then we
have:
RtotðtÞ max
kin
kout
;
kin
keðRLÞ
  
fort 0: ð75Þ
Proof Adding the last two equations of the system (1), we
obtain
dRtot
dt
¼ kin   koutR   keðRLÞRL ð76Þ
We now consider two cases: (I) ke(RL) C kout and (II)
ke(RL)\kout
Case I (ke(RL) C kout). We write Eq. (76)a s
dRtot
dt
¼ kin   koutRtot þð kout   keðRLÞÞRL ð77Þ
and conclude that since, by assumption, ke(RL) C kout,w eh a v e
dRtot
dt
 kin   koutRtot ð78Þ
Deﬁne the function q1ðtÞ¼
def RtotðtÞ R0: Then, transforming
Eq. (78) and the initial value of Rtot to this new variable, we
obtain
dq1
dt
  koutq1; q1ð0Þ¼0 ð79Þ
This implies that
d
dt
ekouttq1ðtÞ
  
 0 and henceq1ðtÞ q1ð0Þ¼0
Therefore,
RtotðtÞ R0 ¼
kin
kout
ð80Þ
as asserted. This completes the proof of the ﬁrst inequality.
h
Case II (ke(RL)\kout). We now write Eq. (76)a s
dRtot
dt
¼ kin   keðRLÞRtot þð keðRLÞ   koutÞRL
\kin   keðRLÞRtot
ð81Þ
Put q2ðtÞ¼
def RtotðtÞ R ; where R* = kin/ke(RL), and note
that by assumption, q2(0) = Rtot(0) - R*\0. Proceeding
as in the previous case we conclude that q2(t)\0 for t C 0
and hence that
RtotðtÞ\
kin
keðRLÞ
for allt 0 ð82Þ
This completes the proof of the second inequality, and
hence of the lemma. h
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(1) The upper bound in Lemma 1 is independent of the
amount of ligand that is supplied to the system and it is
valid whether drug is given through a bolus adminis-
tration or by means of a constant rate infusion.
(2) Lemma 1 generalises an observation made before in
[3, 15, 17], which states that
RtotðtÞ R0 if and only if keðRLÞ ¼ kout ð83Þ
Next, we prove bounds for R.
Lemma 2 Suppose that L(0) = L0, R(0) = R0
and RL(0) = 0. Then
R0
1 þ
kon
kin
L0
R0
\RðtÞ\R0 1 þ Kd
kon
kout
L0
R0
  
for0 t\1
ð84Þ
Proof From the conservation law (4) we deduce that
Ltot(t) is a decreasing function of t. Therefore,
LðtÞþRLðtÞ L0 for allt 0 ¼) RLðtÞ L0 ð85Þ
In order to prove the upper bound, we write
dR
dt
¼ kin   koutR   konL   R þ koffRL
\kin   koutR þ koffRL
\ðkin þ koffL0Þ koutR ¼ koutðRþ   RÞ
ð86Þ
where
Rþ ¼
kin þ koffL0
kout
ð87Þ
Plainly R(0) = R0\R?, and we claim that R(t)\R? for
all t C 0. Suppose to the contrary that there exists ﬁrst a
time t0[0 such that R(t0) = R?, i.e.,
RðtÞ\Rþ for0\t\t0 and Rðt0Þ¼Rþ ð88Þ
We see that R(t) approached R? from below as t % t0; so
that dR/dt C 0a tt = t0. However, we deduce from (86)
that dR/dt(t0)\0. Therefore, we have a contradiction and
we may conclude that there exists no time t0[0 for which
R(t) attains the value R?. This proves the claim and thereby
the upper bound. h
To prove the lower bound we write
dR
dt
¼ kin   koutR   konL   R þ koffRL
[kin   koutR   konL   R
[kin  ð kout þ konR0ÞR ¼ð kout þ konR0ÞðR    RÞ
ð89Þ
where
R  ¼
kin
kout þ konL0
ð90Þ
Proceeding as with the upper bound, we establish the lower
bound.
Corollary 1 Since R?(L0) ? R0 and R-(L0) ? R0 as L0
? 0, it follows that for any time t C 0,
RðtÞ!R0 asL0 ! 0 ð91Þ
Appendix 4: Derivation of the approximation Lapprox(t)
and expressions for AULC and CL
We wish to solve the initial value problem
dL
dt
¼  keðLÞL   kin; Lð0Þ¼L ð92Þ
where L   L0   R0 is the ligand concentration right after
Phase A. We multiply this equation by ekeðLÞt to obtain
d
dt
ðekeðLÞtLÞ¼ekeðLÞtkin
Integration over (0,t) yields the desired expression for the
solution Lapprox(t) of Eq. (92):
LapproxðtÞ¼ð L þ mÞe keðLÞt   m; m ¼
kin
keðLÞ
ð93Þ
Plainly, L(t) ? - m\0a st !1 : Since Lapprox(t)i s
decreasingand L(0)[0, it follows that thereexistsaunique
time T
*[0 for which Lapprox(t) vanishes. An elementary
computation yields the following expression for T
*:
T  ¼
1
keðLÞ
ln
L
m
þ 1
  
¼
1
keðLÞ
ln
keðLÞ
kin
L þ 1
  
ð94Þ
For the three largest initial ligand concentrations used in
case study this formula yields, as L0 decreases, respec-
tively, T
* & 2818 h, T
* & 2042 h and T
* & 1372 h. This
agrees well with the numerical results shown in Figs. 3, 4
and 5.
In order to derive the approximation for AULC(L0), we
write
Z T 
0
LapproxðtÞdt ¼
1
keðLÞ
Z keðLÞT 
0
fðL þ mÞe s   mgds
¼
1
keðLÞ
fðL þ mÞð1   e keðLÞT 
Þ mkeðLÞT g
ð95Þ
When we now substitute the expression for T
* from (94)
into (95), we obtain the desired formula:
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123AULCðL0Þ¼
1
keðLÞ
L0   R0   mlog
L0   R0 þ m
m
     
ð96Þ
from which (28) follows. Applying the deﬁnition
CL(D) = D/AULC(D) we obtain an expression for CL(D).
Appendix 5: Small ligand asymptotics
When, as in Phases C and D, the ligand concentration
drops to levels that are comparable to Kd, a different
scaling from the one used in Appendix 2 yields information
about the relative importance of the different processes. For
this range we deﬁne the scaling
u ¼
L
Kd
; v ¼
R
R0
; w ¼
RL
R0
ð97Þ
which, after substitution into the system (9) yields
du
dt ¼  konR0ðu   v   wÞ keðLÞu
dv
dt ¼ koutð1   vÞ koffðu   v   wÞ
dw
dt ¼ koffu   v  ð koff þ keðRLÞÞw
8
> > > <
> > > :
ð98Þ
In addition we need to introduce a new, more appropriate,
time scale for this phase. As we shall see, 1/koff will be the
right choice for this stage in the dynamics, and we deﬁne
the new dimensionless time
s ¼ kofft ð99Þ
When we introduce this time variable into the system
(98) we obtain
edu
ds ¼  u   v þ w   eau
dv
ds ¼ bð1   vÞ ð u   v   wÞ
dw
ds ¼ u   v  ð 1 þ cÞw
8
> > > <
> > > :
ð100Þ
where e;a;b and c are been deﬁned as in (58) and (65):
e ¼
Kd
R0
; a ¼
keðLÞ
koff
; b ¼
kout
koff
and c ¼
keðRLÞ
koff
ð101Þ
Note that for the parameter values listed in Table 1, we have
e ¼ 0:0009; a ¼ 1:5; b ¼ 9; c ¼ 3
Thus, e is very small so that we may conclude from a
standard singular perturbation argument [19, 20, 21] that
after a very short period
u   v   w ¼ 0o rL   R ¼ Kd   RL ð102Þ
The equality (102) enables us to simplify the second and
third equation of the system (100)t o
dv
ds
¼ bð1   vÞ and
dw
ds
¼  cw ð103Þ
or, in terms of the original variables,
dR
dt
¼ koutðR0   RÞ and
dRL
dt
¼  keðRLÞRL ð104Þ
Since at the start of Phase C we have R & 0 and RL &
R*, we conclude that
RðtÞ R0ð1   e kouttÞ and RLðtÞ R e keðRLÞt ð105Þ
Appendix 6: Derivation of the steady state relations (47)
and (48)
Whenweputthederivativesinthesystem(46)equaltozeroand
put twashout ¼1 ; we obtain a nonlinear algebraic system of
three equations involving the three variables L, R, RL.W e
eliminate L and Rand derive the expression (47) for the steady
statevalueofRL.Addingtheﬁrstandthethirdequationof(46)
yields a relation that involving only RL and L:
kf ¼ keðRLÞRL þ keðLÞL ð106Þ
Adding the second and the third equation of (46) yields a
relation involving only terms of R and RL:
kin ¼ keðRLÞRL þ koutR ð107Þ
Using these two relations to eliminate R and L from the ﬁrst
equation, we obtain a quadratic equation for RL:
X2 þð kf þ kin þ qÞX þ kfkin ¼ 0; X ¼ keðRLÞRL ð108Þ
where q = (ke(L)/ke(RL))koutKm. Plainly, it has two distinct
roots, RL? and RL- and they are endowed with the property
keðRLÞðRLþ þ RL Þ¼kf þ kin þ q ð109Þ
Adding (106) and (107) we deduce that the steady state
value of RL must satisfy the inequality
2keðRLÞRL\kf þ kin ð110Þ
This implies that the desired steady state value of RL must
be given by the smaller of the two roots: RL-. The two
expressions (106) and (107) then yield the corresponding
steady state values for L and R.
Appendix 7: Computation of the terminal slope
In order to compute the terminal slope kz for the ligand
concentration proﬁle we linearise the system (9) about the
steady state (L, R, RL) = (0, R0, 0). Writing L = n,
R = R0 ? g and RL ¼ f; we obtain the linear system
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dt ¼  ð konR0 þ keðLÞÞn þ kofff
dg
dt ¼  konR0n   koutg þ kofff
df
dt ¼ konR0n  ð koff þ keðRLÞÞf
8
> > > > <
> > > > :
ð111Þ
when higher order terms are omitted. It is convenient to
write this system in vector- and matrix notation:
dY
dt
¼ AY where Y ¼
n
g
f
0
@
1
A ð112Þ
and A is the coefﬁcient matrix of the linear system (111):
A ¼
 ðkonR0 þ keðLÞÞ 0 koff
 konR0  kout koff
konR0 0  ðkoff þ keðRLÞÞ
0
@
1
A
ð113Þ
We assume that the matrix -A has three distinct
eigenvalues k1, k2 and k3 and that Y1, Y2 and Y3 are the
corresponding eigenvectors. The General Solution of Eq.
(112) then takes the form
YðtÞ¼C1Y1e k1t þ C2Y2e k2t þ C3Y3e k3t ð114Þ
where C1, C2 and C3 are arbitrary constants.
The eigenvalues ki (i = 1, 2, 3) are the roots of the
equation
detðA þ kIÞ¼0
Thus, we ﬁnd that
k1 ¼ kout
and k2 and k3 are the roots of the quadratic equation
k
2   ak þ b ¼ 0 ð115Þ
where
a¼konR0 þkeðLÞ þkoff þkeðRLÞ ¼konR0 1þeaþeð1þcÞ fg
b¼konR0keðRLÞ þkeðLÞkoff þkeðLÞkeðRLÞ
¼konR0keðRLÞ 1þe
a
c
ð1þcÞ
  
ð116Þ
and e;a;b and c are deﬁned in Eqs. (58) and (64). Since
e 1 and a, b and c are of moderate size (cf. Assumptions
A and B in (13)), we have to good approximation,
a ¼ konR0 and b ¼ konR0keðRLÞ ð117Þ
This implies that b=a2 ¼ ec   1; so that we conclude that
k1 ¼ kout ¼ 0:0089; k2 ¼ a ¼ konR0 ¼ 0:11 and
k3 ¼
b
a
¼ keðRLÞ ¼ 0:003
ð118Þ
i.e., the terminal slope kz is given by kz = ke(RL) = 0.003.
This agrees with the numerical value found in Figs. 5, 6, 7
and 8. For an earlier derivation we refer to [25].
Remark Naturally,whenke(RL) = 0thenligandwillstillleak
out of the system, albeit more slowly, thanks to direct elimi-
nation of ligand. For this case we obtain the following terminal
slope:
kz ¼
b
a
¼ keðLÞ
Kd
R0
: ð119Þ
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